SCHEMBL26962143

SCHEMBL26962143

CC(C)(C)OC(=O)N[C@H]1CSc2cc(Br)c(C(=O)O)cc2NC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.40
▸ EPHX2 P34913 1/20 0.35
▸ NFKB1 P19838 1/20 0.34
▸ NFKB2 Q00653 1/20 0.34
▸ RELA Q04206 1/20 0.34
▸ IDO1 P14902 1/20 0.33
▸ CTSD P07339 3/20 0.31
▸ BACE1 P56817 2/20 0.31
▸ LCK P06239 1/20 0.31
▸ FYN P06241 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ CA12 O43570 1/20 0.30
▸ CA1 P00915 1/20 0.30
▸ CA2 P00918 1/20 0.30
▸ CA3 P07451 1/20 0.30
▸ CA4 P22748 1/20 0.30
▸ CA6 P23280 1/20 0.30
▸ CA5A P35218 1/20 0.30
▸ CA7 P43166 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29796833 0.91 GAA (0.40) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL26961952 0.88 GAA (0.41) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL20263891 0.88 GAA (0.40) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL20263999 0.88 GAA (0.40) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL27121024 0.88 GAA (0.40) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL25766630 0.86 GAA (0.41) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL25761124 0.86 GAA (0.41) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL29796701 0.84 GAA (0.41) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL26961700 0.84 GAA (0.41) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL29797040 0.83 GAA (0.37) GAAEPHX2NFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4291558-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2023-12-20 — — EP disclosed
Send feedback